CLINICAL TRIAL / NCT06423911
Study of Olverembatinib (HQP1351) in Patients With CP-CML
- Interventional
- Recruiting
- NCT06423911
Contact Information
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia
A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)